Navigation Links
CeNeRx BioPharma Completes $4.85 Million Financing
Date:12/9/2011

RESEARCH TRIANGLE PARK, N.C., Dec. 9, 2011 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $4.85 million financing.  Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners, Pappas Ventures and Omega Funds all participated in the financing.  CeNeRx plans to use the proceeds to complete its ongoing Phase II trial of the improved formulation of its novel antidepressant TriRima™ as monotherapy in treatment resistant depression, as well as to support advancement of its pipeline of promising agents for a variety of CNS disorders.

"Our Phase II trial of TriRima in treatment resistant depression is proceeding very well and these funds will primarily be used to help complete the study," said Barry Brand, Chief Executive Officer of CeNeRx.  "The pace of enrollment has been excellent – we have enrolled almost 80% of the 360 patients targeted for this trial and hope to complete the study and report headline data by mid-2012." 

Treatment resistant depression represents a large and serious problem, with between 30-50% of depressed patients not responding to traditional antidepressant therapy.  The only FDA-approved medications for treatment resistant depression are atypical antipsychotics, which are associated with significant safety concerns such as tardive dyskinesia, metabolic syndrome, hypoglycemia and diabetes.  TriRima has the opportunity to fill this therapeutic gap and to be the first monotherapy for treatment resistant depression that avoids the safety issues of the atypical antipsychotics. 

Mr. Brand continued, "As expected, thus far in this Phase II trial we have seen no signs of the food-associated hypertensive effects of conventional MAO inhibitors.  In addition, blinded assays of the subjects i
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Publication in Neuropsychopharmacology Confirms CeNeRxs Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
2. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
3. CeNeRx BioPharma Completes $15 Million Series B Financing
4. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Windhover Announces the "Top Biopharma Projects to Watch"
7. Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin
8. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
9. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
10. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
11. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
(Date:12/24/2014)... December 23, 2014 “Preparative & ... HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, ... & Agriculture) - Forecasts to 2019” provides a ... opportunities, current market trends, and strategies impacting the ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... A new nanoscale device developed by a University of ... individual flowing electrons in such devices as laptop computers ... and communication. This device will allow researchers ... influence of heat dissipation on single electron transport in ...
... EraGen Biosciences, Inc. announced today that it has ... Gene-Code(TM) technology. The test is now in the hands of ... is being shipped to WHO Central Public Health Laboratory (UK) ... the recent sequencing of the SARS genome, EraGen went to ...
... WI.- Whatever was goin down at the first-ever Wisconsin Entrepreneurs ... good to see people smiling about what they were doing ... a couple roommates of mine hatched a plan to rid ... whose sheer powers of multiplication were quickly making it the ...
Cached Biology Technology:Cool Computers 2Cool Computers 3EraGen Biosciences Ships SARS Diagnostic Test in Record Time 2Entrepreneurial Spirit Infectious in Milwaukee 2Entrepreneurial Spirit Infectious in Milwaukee 3
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in the APAC ... One major trend emerging in this market is advances ... important to upgrade biometric solutions to the latest standard ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Fisher, associate professor in the Fischell Department of Bioengineering, ... Research and Technology Review Day with a tissue engineering ... tissue for implantation. Fisher,s technology was one of ... faculty members and graduate students at the Professor Venture ...
... the $40-million-per-year culinary trade of frog legs in some ... France, Belgium and the United States. Scientists at the ... is a potential carrier of pathogens deadly to amphibians. ... Frontiers in Ecology , Thursday, Nov. 19. ...
... on Skin of Amphibians May Protect Against Lethal Fungus ... bacteria on the skin of salamanders could help protect ... a lethal skin disease. The researchers from James ... report their findings in the November 2009 issue of ...
Cached Biology News:Bioreactor for bone tissue engineering wins professor venture fair 2Bioreactor for bone tissue engineering wins professor venture fair 3Smithsonian scientists find the frog legs trade may facilitate spread of pathogens 2Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Tips from the Journals of the American Society for Microbiology 4
...
... atoms at the 3, 3', 4, and ... as an internal standard for the quantification ... PGE1 is the theoretical cyclooxygenase metabolite of ... undetectable in the plasma of normal humans ...
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Direct ELISA Assay Diluent, 10 L...
Biology Products: